Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
43.4M
-
Number of holders
-
89
-
Total 13F shares, excl. options
-
19.5M
-
Shares change
-
+3.48M
-
Total reported value, excl. options
-
$294M
-
Value change
-
+$50M
-
Put/Call ratio
-
0.71
-
Number of buys
-
47
-
Number of sells
-
-40
-
Price
-
$15.05
Significant Holders of Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) as of Q3 2020
109 filings reported holding CUE - Cue Biopharma, Inc. - Common Stock, $0.001 par value per share as of Q3 2020.
Cue Biopharma, Inc. - Common Stock, $0.001 par value per share (CUE) has 89 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.5M shares
of 43.4M outstanding shares and own 44.96% of the company stock.
Largest 10 shareholders include Nantahala Capital Management, LLC (2.34M shares), BlackRock Inc. (2.12M shares), Avoro Capital Advisors LLC (1.87M shares), Slate Path Capital LP (1.48M shares), Corriente Advisors, LLC (1.44M shares), VANGUARD GROUP INC (1.38M shares), STATE STREET CORP (1.35M shares), Woodline Partners LP (915K shares), Prosight Management, LP (710K shares), and Robertson Stephens Wealth Management, LLC (484K shares).
This table shows the top 89 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.